Tenax Therapeutics is trading 5.83% up at $1.91, with the move appearing to be a volatile rebound following the August 10 Phase 3 LEVEL trial failure.
- After opening August 17, 2026, shares were above the August 14 close of $1.80.
- No new company-specific announcement directly explaining the gain was identified.
- RTW Investments’ August 14 disclosure of a 9.99% passive stake may be supporting sentiment.